Pacific Edge Limited · NZX:PEB
Pacific Edge — Corporate Update (December 2019)
5 slides from Pacific Edge's corporate update, December 2019
Slide 1: Executive Update
U P D AT E DECEMBER 2019 EXECUTIVE UPDATE David Darling, Chief Executive Officer We were pleased to announce our FY20 half year results on 21 November 2019, reporting increased cash receipts, revenue and laboratory throughput as our Cxbladder diagnostic tests are adopted into guidelines in the USA a
Slide 2: Half Year Snapshot and Total Laboratory Throughput Comparison
The annual addressable market for our suite Total Laboratory Throughput Comparison HALF YEAR SNAPSHOT of Cxbladder products was estimated by EY Parthenon as being US$1.2 billion1. We are focused on completing agreements for the Total Laboratory Throughput Comparison Full Year Comparison For the six
Slide 3: Growing Momentum in New Zealand; Compelling Evidence Supports Cxbladder
GROWING MOMENTUM IN NEW ZEALAND COMPELLING EVIDENCE SUPPORTS CXBLADDER CXBLADDER ADOPTED BY NEW ZEALAND’S PUBLIC HEALTHCARE PROVIDERS UROTODAY VIDEO PRESENTATION Validation from the New Zealand market continues Many of the healthcare providers in Pacific Edge’s In May 2019, a paper published in the
Slide 4: Why a Placement and a Rights Issue to Raise $20 Million in New Capital?
WHY A PLACEMENT AND A By undertaking the capital raising in two components - a Placement of new shares In any capital raising where there is an increase in the total number of the shares in INTRODUCING OUR TEAM RIGHTS ISSUE TO RAISE and a Rights Issue for existing shareholders - the market, then the
Slide 5: Winner of the Excellence in Innovation Award 2019
PACIFIC EDGE IS HONOURED TO HAVE BEEN ANNOUNCED AS THE WINNER OF THE EXCELLENCE IN INNOVATION AWARD 2019
Pacific Edge — Corporate Update (December 2019) on 6ix